Therapy Areas: Inflammatory Diseases
CETF announces promising early treatment from fluvoxamine in patients with mild COVID-19
7 October 2020 -

The COVID-19 Early Treatment Fund (CETF) stated on Tuesday that fluvoxamine was shown to significantly reduce the likelihood of hospitalization, if given early to patients with mild COVID-19, in a recent funded outpatient clinical trial at Washington University in St. Louis.

In the clinical trial, which was conducted by Dr Eric Lenze, director of the Healthy Mind Lab at Washington University in St. Louis, about 152 people were diagnosed with mild forms of COVID-19 and lived in either Missouri or Illinois. The participants were randomly assigned (1:1) to take either fluvoxamine or a placebo. The results suggest that fluvoxamine may mitigate the risk of hospitalization and death.

On 6 October 2020, researchers from the Washington University School of Medicine shared the new data at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group virtual conference on Therapeutics for COVID-19.

Fluvoxamine, a repurposed drug, could prevent COVID-19 patients from developing more severe symptoms. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), a class of anti-depressants, mostly prescribed for people suffering from an obsessive-compulsive disorder. It was tested in coronavirus patients because fluvoxamine has very strong anti-inflammatory properties, which could prevent cytokine storms – the body's massive, sometimes deadly, inflammatory reaction to coronavirus and other infections, added CETF.

CETF was created to ensure the rapid and successful completion of outpatient clinical trials that lead to effective early treatments for COVID-19, using existing drugs. This offers the shortest path to saving lives, by bringing new treatments online within a matter of months.



Related Headlines